Eli Lilly and Company
Lilly unites caring with discovery to create medicines that make life better for people around the world.
www.lilly.comHere are the latest notable developments for Eli Lilly and Company (LLY) as of 2026, based on recent public reporting:
-
Q2 2025/2026 updates and pipeline progress: Lilly has continued to report strong growth across its diabetes and obesity franchises (Mounjaro/Tirzepatide and Zepbound) with ongoing pipeline momentum, including potential new indications and expansions in cardiovascular and oncology areas. Expect continued quarterly updates and investor-focused disclosures around revenue mix, pipeline milestones, and manufacturing investments.[3][4]
-
Acquisitions and corporate moves: Lilly announced several strategic acquisitions in 2024–2025 to broaden its portfolio in inflammatory diseases, cardiovascular care, and genetic medicines (e.g., Morphic in 2024 and Verve Therapeutics in 2025). These moves aim to diversify therapeutic areas and accelerate growth, with accompanying leadership transitions and governance updates.[2][4][3]
-
Pricing and access initiatives: Lilly has pushed pricing and affordability efforts for insulin and other therapies amid public and policy scrutiny, including caps or price adjustments to improve patient access, which has been a recurring theme in their public communications and press releases.[1]
-
Financial results and guidance: The company has periodically raised or re-affirmed full-year revenue guidance in line with product performance, pipeline progress, and manufacturing scale-up, supported by elevated demand for diabetes and obesity drugs and expanded manufacturing capacity in sites like Lebanon, Indiana, and Kenosha County.[4][2]
-
Leadership and governance: In 2025, Lilly announced executive leadership transitions to strengthen long-term growth, with board composition updates and strategy realignment to sustain global access and pipeline execution.[3]
If you’d like, I can pull the most recent press releases or a quick, 1-page summary with dates, key figures, and pipeline highlights. I can also assemble a brief timeline of major milestones from 2024–2026 with citations.